Albert Labs International Corp (CSE:ABRT) said it has strengthened its Scientific Advisory Board with the addition of two renowned scientists, Professor Robert Britton and Dr Ricardo Jorge Dinis-Oliveira.
The company noted that Britton is a natural product chemist with globally recognized expertise in natural product drug discovery, medicinal chemistry, and cancer therapeutics, with a particular focus on oncology.
He is experienced in creating new processes for improving the manufacturing of drugs and new strategies for synthesizing structurally complex natural products.
READ: Albert Labs files provisional patent in the US for its Psilocybe mycelia cultivation process
Albert Labs said Dinis-Oliveira is an expert toxicologist and pharmacologist, with a focus on the toxicology and pharmacology of psychoactive substances.
Having written more than 170 published articles, he was included in the world's top 2% of Scientists List in 2021.
Albert Labs CEO Michael Raymont noted that Britton and Dinis-Oliveira’s in depth-knowledge of natural product medicines and toxicology and pharmacology respectively would complement the expertise of the company’s other Scientific Advisory Board members.
“Improving drug discovery, and gaining a better understanding and depth of these compounds’ pharmacodynamics and toxicology is critical to building value for Albert Labs shareholders as we advance towards our goal of delivering safe and effective drugs to revolutionize mental health treatment,” he said in a statement.
Britton added that he was excited to be working with Albert Labs to create new medications for patients with unmet medical needs. “Fungi have been an important source of new medicines are on the whole, pharmaceutically prolific and extremely promising,” he said.
Dinis-Oliveira explained that he and his team would complete thorough toxicological and pharmaceutical testing to ensure Albert Labs’ clinical work was delivered safely and effectively.
“I am looking forward to assisting a company that will be safely administering psilocybin as a complement to psychotherapy and other pharmacological chemical treatments for people with urgent and unmet needs,” Dinis-Oliveira said.
Based in Vancouver, Albert Labs is a clinical research and drug development enterprise that is fast-tracking the development of mental health medicines with its focus on real-world evidence.
Contact Emily at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie